RESUMEN
The 5-hydroxytryptamine (5-HT) (serotonin) 5-HT3 receptor represents a clinical target for antagonists to deliver symptomatic relief to patients with diarrhea-predominant irritable bowel syndrome (IBS-d) or carcinoid syndrome. Unfortunately, this pharmacological strategy can present side effects (e.g., severe constipation). The present study investigates the potential of a novel 5-HT3 receptor partial agonist, CSTI-300, to treat patients with IBS-d and other conditions associated with discomfort from colonic distension, with a predicted reduced side-effect profile. The in vitro and in vivo preclinical pharmacology of the drug CSTI-300 was investigated to explore the potential to treat patients with IBS-d. CSTI-300 displayed selective high affinity for the human and rat 5-HT3 receptor (Ki approximately 2.0 nM) and acted as a partial agonist (approximately 30%-50% intrinsic efficacy) in vitro. In an in vivo model of IBS-d, the rat colon distension model, CSTI-300 displayed dose-dependent efficacy. In addition, oral administration of CSTI-300 to dogs that achieved plasma levels of the drug exceeding the Ki value for the 5-HT3 receptor failed to either evoke emesis or alter the state of feces. Pharmacokinetics for CSTI-300 in rat and dog identified high levels of oral availability with t 1/2 range of 1.6-4.4 hours. The preclinical pharmacology of the lead candidate drug, CSTI-300, supports the potential of this novel drug to offer symptomatic relief to patients with irritable bowel syndrome and carcinoid syndrome with a rationale for a reduced "on-target" side-effect profile relative to 5-HT3 receptor antagonists, such as alosetron. SIGNIFICANCE STATEMENT: There is a lack of effective current treatment for diarrhea-predominant irritable bowel syndrome and carcinoid syndrome, and in both conditions, overactivity of the 5-hydroxytryptamine (5-HT) 5-HT3 receptor is thought to be implicated in the pathophysiology. Because 5-HT3 receptor blockade with antagonists results in significant side effects, we present evidence that treatment with a suitable 5-HT3 receptor partial agonist will alleviate some symptoms associated with these conditions yet, without fully inhibiting the receptor, predict a less pronounced side-effect profile associated with this therapeutic strategy.
Asunto(s)
Agonismo Parcial de Drogas , Compuestos Heterocíclicos con 3 Anillos/química , Compuestos Heterocíclicos con 3 Anillos/uso terapéutico , Síndrome del Colon Irritable/tratamiento farmacológico , Síndrome Carcinoide Maligno/tratamiento farmacológico , Agonistas del Receptor de Serotonina 5-HT3/química , Agonistas del Receptor de Serotonina 5-HT3/uso terapéutico , Animales , Perros , Relación Dosis-Respuesta a Droga , Células HEK293 , Humanos , Síndrome del Colon Irritable/fisiopatología , Masculino , Síndrome Carcinoide Maligno/fisiopatología , Ratas , Ratas Sprague-Dawley , Resultado del TratamientoRESUMEN
Clinical development of drugs for CNS disorders can be a challenging and risky endeavor. In this article we look at the steps required to move a preclinical candidate compound into clinical development. We use the case study of ALB-127158(a), an MCH1 antagonist for the treatment of obesity via a central mechanism to highlight the steps needed to move into early clinical development. Preclinical studies demonstrated that the compound produced significant weight loss in rodents. Based on the observation that the weight loss was caused by a reduction in food intake it was possible to build measures of ingestive behavior into the early clinical development plan. Single and multiple ascending dose studies were conducted in normal and overweight volunteers. The compound was safe and well tolerated with good PK characteristics. ALB-127158(a) was shown to have some effects on measures of 'hunger' and 'desire to eat', unfortunately these effects only occurred at doses higher than those predicted from the preclinical studies. A subsequent study looking at compound levels in the cerebrospinal fluid (CSF) suggested lower brain exposure than seen in the preclinical models. Based on this data and the limited efficacy observed it was possible to terminate further progression of this compound for obesity before costly long-term weight loss studies were initiated. However, recent reports have demonstrated that MCH acting via MCH1 receptors located on intestinal epithelial cells may be a critical mediator of inflammatory responses within the gastrointestinal (GI) tract. MCH1 receptor antagonists may therefore have a beneficial effect in disorders such as inflammatory bowel disease (IBD). Based on this evidence a peripherally selective MCH1 receptor antagonist such as ALB-127158(a) may be a potential treatment for IBD. This example demonstrates how using data from the preclinical studies is possible to build decision points into an early clinical development plan that will allow early assessment of potential efficacy and allow timely go/no go decisions.
Asunto(s)
Fármacos Antiobesidad/uso terapéutico , Ensayos Clínicos como Asunto , Descubrimiento de Drogas/normas , Evaluación Preclínica de Medicamentos , Indazoles/uso terapéutico , Obesidad/tratamiento farmacológico , Piridonas/uso terapéutico , Animales , Humanos , Masculino , Ratas , Receptores de la Hormona Hipofisaria/antagonistas & inhibidoresRESUMEN
Serotonin type 3 (5-HT3) receptor partial agonists have been targeted as potential new drugs for the symptomatic relief of irritable bowel syndrome (IBS). Multiple diazepinone-based compounds have been discovered, which exhibit nanomolar binding affinity for the h5-HT3A receptor and display a range of intrinsic activities (IA=7-87% of 5-HT Emax) in HEK cells heterologously expressing the h5-HT3A receptor. Favorable physicochemical properties and in vitro ADME profile coupled with oral activity in the murine von Bezold-Jarisch reflex model demonstrates the series has promise for producing low to moderate IA partial agonists suitable for an IBS indication.
Asunto(s)
Azepinas/farmacología , Descubrimiento de Drogas , Síndrome del Colon Irritable/tratamiento farmacológico , Receptores de Serotonina 5-HT3/metabolismo , Administración Oral , Animales , Azepinas/administración & dosificación , Azepinas/química , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Células HEK293 , Humanos , Ratones , Estructura Molecular , Relación Estructura-ActividadRESUMEN
The sodium glucose co-transporter 2 (SGLT2) has received considerable attention in recent years as a target for the treatment of type 2 diabetes mellitus. This report describes the design, synthesis and structure-activity relationship (SAR) of C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties as novel SGLT2 inhibitors. Compounds 5p and 33b demonstrated high potency in inhibiting SGLT2 and high selectivity against SGLT1. The in vitro ADMET properties of these compounds will also be discussed.
Asunto(s)
Diseño de Fármacos , Glicósidos/farmacología , Fenitoína/análogos & derivados , Piridonas/farmacología , Inhibidores del Cotransportador de Sodio-Glucosa 2 , Triazoles/farmacología , Relación Dosis-Respuesta a Droga , Glicósidos/síntesis química , Glicósidos/química , Humanos , Estructura Molecular , Fenitoína/química , Fenitoína/farmacología , Piridonas/síntesis química , Piridonas/química , Transportador 2 de Sodio-Glucosa , Relación Estructura-Actividad , Triazoles/síntesis química , Triazoles/químicaRESUMEN
Hyperactivity of serotonin 3 receptors (5-HT3R) underlies pathologies associated with irritable bowel syndrome and chemotherapy-induced nausea and vomiting. Setrons, a class of high-affinity competitive antagonists, are used in the treatment of these conditions. Although generally effective for chemotherapy-induced nausea and vomiting, the use of setrons for treating irritable bowel syndrome has been impaired by adverse side effects. Partial agonists are now being considered as an alternative strategy, with potentially less severe side effects than full antagonists. However, a structural understanding of how these ligands work is lacking. Here, we present high-resolution cryogenic electron microscopy structures of the mouse 5-HT3AR in complex with partial agonists (SMP-100 and ALB-148471) captured in pre-activated and open-like conformational states. Molecular dynamics simulations were used to assess the stability of drug-binding poses and interactions with the receptor over time. Together, these studies reveal mechanisms for the functional differences between orthosteric partial agonists, full agonists and antagonists of the 5-HT3AR.
Asunto(s)
Antineoplásicos , Síndrome del Colon Irritable , Ratones , Animales , Serotonina/farmacología , Vómitos , NáuseaRESUMEN
Psilocybin produces an altered state of consciousness in humans and is associated with complex spatiotemporal changes in brain networks. Given the emphasis on rodent models for mechanistic studies, there is a need for characterization of the effect of psilocybin on brain-wide network dynamics. Previous rodent studies of psychedelics, using electroencephalogram, have primarily been done with sparse electrode arrays that offered limited spatial resolution precluding network level analysis, and have been restricted to lower gamma frequencies. Therefore, in the study, we used electroencephalographic recordings from 27 sites (electrodes) across rat cortex (n=6 male, 6 female) to characterize the effect of psilocybin (0.1 mg/kg, 1 mg/kg, and 10 mg/kg delivered over an hour) on network organization as inferred through changes in node degree (index of network density) and connection strength (weighted phase-lag index). The removal of aperiodic component from the electroencephalogram localized the primary oscillatory changes to theta (4-10 Hz), medium gamma (70-110 Hz), and high gamma (110-150 Hz) bands, which were used for the network analysis. Additionally, we determined the concurrent changes in theta-gamma phase-amplitude coupling. We report that psilocybin, in a dose-dependent manner, 1) disrupted theta-gamma coupling [p<0.05], 2) increased frontal high gamma connectivity [p<0.05] and posterior theta connectivity [p≤0.049], and 3) increased frontal high gamma [p<0.05] and posterior theta [p≤0.046] network density. The medium gamma frontoparietal connectivity showed a nonlinear relationship with psilocybin dose. Our results suggest that high-frequency network organization, decoupled from local theta-phase, may be an important signature of psilocybin-induced non-ordinary state of consciousness.
RESUMEN
The design, synthesis, and structure-activity relationships (SAR) of a series of N-((1-(4-(propylsulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide inhibitors of glycine transporter-1 (GlyT-1) are described. Optimization of the benzamide and central ring components of the core scaffold led to the identification of a GlyT-1 inhibitor that demonstrated in vivo activity in a rodent cerebral spinal fluid (CSF) glycine model.
Asunto(s)
Benzamidas/química , Benzamidas/farmacología , Proteínas de Transporte de Glicina en la Membrana Plasmática/antagonistas & inhibidores , Animales , Benzamidas/síntesis química , Glicina/líquido cefalorraquídeo , Proteínas de Transporte de Glicina en la Membrana Plasmática/metabolismo , Células HEK293 , Humanos , Microsomas Hepáticos/metabolismo , Piperazinas/síntesis química , Piperazinas/química , Piperazinas/farmacología , Ratas , Relación Estructura-ActividadRESUMEN
There is a renewed interest in psychedelic drugs as potential therapeutic agents for the treatment of psychiatric disorders. In particular, psilocybin has shown promise for the treatment of refractory depression1 and major depressive disorder2, and has also been explored as a treatment for tobacco and alcohol abuse3,4. However, despite suggestive evidence5,6, there has been no systematic study to investigate the effectiveness of psilocybin in attenuating indices of chronic pain. To address this gap, we investigated the effect of psilocybin on mechanical hypersensitivity and thermal hyperalgesia in a well-established rat model of formalin-induced, centralized chronic pain7,8 and demonstrate that a single intravenous bolus administration of psilocybin can attenuate mechanical hypersensitivity for 28 days.
Asunto(s)
Dolor Crónico , Trastorno Depresivo Mayor , Alucinógenos , Humanos , Animales , Ratas , Psilocibina/farmacología , Psilocibina/uso terapéutico , Trastorno Depresivo Mayor/tratamiento farmacológico , Dolor Crónico/tratamiento farmacológico , Alucinógenos/farmacología , Alucinógenos/uso terapéutico , FormaldehídoRESUMEN
A new series of epiminocyclohepta[b]indoles with potent 5-HT(6) antagonist activity were discovered and optimized using in vitro protocols. One compound from this series was progressed to advanced pharmacokinetic (PK) studies followed by 5-HT(6) receptor occupancy studies. The compound was found to have excellent oral absorption, a highly favorable PK profile and demonstrated pharmacodynamic interaction with the 5-HT(6) receptor as shown by ex vivo autoradiography.
Asunto(s)
Indoles/farmacocinética , Receptores de Serotonina/metabolismo , Antagonistas de la Serotonina , Administración Oral , Animales , Células CACO-2 , Humanos , Indoles/administración & dosificación , Indoles/química , Indoles/farmacología , Estructura Molecular , Unión Proteica/efectos de los fármacos , Antagonistas de Receptores Purinérgicos P1 , Ratas , Ratas Sprague-Dawley , Receptores de Serotonina/química , Antagonistas de la Serotonina/administración & dosificación , Antagonistas de la Serotonina/farmacocinética , Antagonistas de la Serotonina/farmacología , Relación Estructura-ActividadRESUMEN
Serotonin type 3 (5-HT(3)) receptor partial agonists are being targeted as potential new drugs for the treatment of irritable bowel syndrome (IBS). Two new chemical series bearing indazole and indole cores have exhibited nanomolar binding affinity for the h5-HT(3)A receptor. A range of partial agonist activities in HEK cells heterologously expressing the h5-HT(3)A receptor were measured for the indazole series. Excellent 5-HT(3) receptor selectivity, favorable in vitro metabolic stability and CYP inhibition properties, and good oral in vivo potency in the murine von Bezold-Jarisch reflex model is exemplified thereby indicating the series to have potential utility as improved IBS agents.
Asunto(s)
Síndrome del Colon Irritable/tratamiento farmacológico , Receptores de Serotonina 5-HT3/química , Agonistas del Receptor de Serotonina 5-HT3/química , Animales , Línea Celular , Modelos Animales de Enfermedad , Humanos , Imidazoles/química , Indoles/química , Ratones , Microsomas Hepáticos/metabolismo , Receptores de Serotonina 5-HT3/metabolismo , Agonistas del Receptor de Serotonina 5-HT3/síntesis química , Agonistas del Receptor de Serotonina 5-HT3/uso terapéuticoRESUMEN
A novel series of Delta9-tetrahydrocannabinol (Delta9-THC) analogues were synthesized to determine their potential as cannabinoid receptor modulators. Chemistry focused on conversion of the phenol of Delta9-THC to other functionality through palladium catalyzed reactions with an intermediate triflate 2. Two analogues with sub 100 nM affinity for the CB1 and CB2 receptors were identified.
Asunto(s)
Dronabinol/síntesis química , Paladio/química , Receptores de Cannabinoides/efectos de los fármacos , Animales , Catálisis , Dronabinol/química , Dronabinol/farmacología , Estructura Molecular , Receptores de Cannabinoides/clasificación , Relación Estructura-ActividadRESUMEN
An indazole based series of glucocorticoid receptor agonists is reported. The SAR exploration of this scaffold yielded compounds with nanomolar affinity for the glucocorticoid receptor with indications of selectivity for the preferred transrepression mechanism; in vivo efficacy was observed in the mouse LPS induced TNFalpha model for compound 28.
Asunto(s)
Antiinflamatorios/química , Indazoles/química , Receptores de Glucocorticoides/agonistas , Animales , Antiinflamatorios/síntesis química , Antiinflamatorios/farmacología , Indazoles/síntesis química , Indazoles/farmacología , Ratones , Receptores de Glucocorticoides/metabolismo , Factor de Necrosis Tumoral alfa/metabolismoRESUMEN
A new series of tetrahydrocarbolines with potent MCH-1 antagonist activity were synthesized, using a conformationally constrained design approach towards optimizing pharmacokinetic properties. Two compounds from this series were progressed to a 5-day diet-induced obesity mouse screening model to evaluate their potential as weight loss agents. Both compounds produced a highly significant reduction in weight, which was attributed to their improved pharmacokinetic profile.
Asunto(s)
Fármacos Antiobesidad/química , Carbolinas/química , Obesidad/tratamiento farmacológico , Receptores de la Hormona Hipofisaria/antagonistas & inhibidores , Animales , Fármacos Antiobesidad/farmacología , Peso Corporal/efectos de los fármacos , Carbolinas/farmacología , Carbolinas/uso terapéutico , Ratones , Relación Estructura-ActividadRESUMEN
A new series of 4-aryl-1-(indazol-5-yl)pyridin-2(1H)ones possessing MCH-1 receptor antagonism is presented. Suzuki coupling of boronic acids with key triflate 6 allowed rapid generation of a range of analogs. The SAR of the MCH-1 receptor was explored with a variety of aryl and heterocyclic moieties. Selected compounds were studied in a five-day diet induced obese mouse model to evaluate their potential use as weight loss agents.
Asunto(s)
Fármacos Antiobesidad/química , Obesidad/tratamiento farmacológico , Piridinas/química , Receptores de la Hormona Hipofisaria/antagonistas & inhibidores , Animales , Fármacos Antiobesidad/farmacología , Ratones , Piridinas/farmacología , Relación Estructura-ActividadRESUMEN
A new series of 5-(pyridinon-1-yl)indazoles with MCH-1 antagonist activity were synthesized. Potential cardiovascular risk for these compounds was assessed based upon their interaction with the hERG potassium channel in a mini-patch clamp assay. Selected compounds were studied in a 5-day diet-induced obese mouse model to evaluate their potential use as weight loss agents. Structural modification of the 5-(pyridinon-1-yl)indazoles to give 5-(furopyridinon-5-yl)indazoles provided compounds with enhanced pharmacokinetic properties and improved efficacy.
Asunto(s)
Indazoles/farmacología , Obesidad/tratamiento farmacológico , Receptores de la Hormona Hipofisaria/antagonistas & inhibidores , Animales , Fármacos Antiobesidad/química , Fármacos Antiobesidad/farmacología , Enfermedades Cardiovasculares/inducido químicamente , Canales de Potasio Éter-A-Go-Go/efectos de los fármacos , Humanos , Indazoles/farmacocinética , Indazoles/uso terapéutico , Ratones , Relación Estructura-ActividadRESUMEN
The original structure of a high-throughput screening hit obtained from an external vendor was revised based on multiple NMR studies. The active compound was re-synthesized via a novel route and its structure and biological activity as a BRS-3 agonist were unambiguously confirmed. Multi-gram quantities of the hit were prepared for pharmacokinetic and efficacy studies. The synthetic strategy allowed for the preparation of multiple analogs for SAR exploration.
Asunto(s)
Fármacos Antiobesidad/síntesis química , Naftiridinas/síntesis química , Pirazoles/síntesis química , Receptores de Bombesina/agonistas , Animales , Fármacos Antiobesidad/química , Fármacos Antiobesidad/farmacocinética , Ensayos Analíticos de Alto Rendimiento , Humanos , Naftiridinas/química , Naftiridinas/farmacocinética , Pirazoles/química , Pirazoles/farmacocinética , Ratas , Receptores de Bombesina/metabolismo , Relación Estructura-ActividadRESUMEN
SAR around non-peptidic potent bombesin receptor subtype-3 (BRS-3) agonist lead 2 is presented. Attempts to replace the carboxylic acid with heterocyclic isosteres to improve oral bioavailability and brain penetration are described.
Asunto(s)
Fármacos Antiobesidad/síntesis química , Imidazoles/química , Receptores de Bombesina/agonistas , Administración Oral , Animales , Fármacos Antiobesidad/química , Fármacos Antiobesidad/uso terapéutico , Encéfalo/metabolismo , Humanos , Imidazoles/síntesis química , Imidazoles/uso terapéutico , Ratones , Obesidad/tratamiento farmacológico , Ratas , Receptores de Bombesina/metabolismo , Relación Estructura-ActividadRESUMEN
This Letter describes a series of potent and selective BRS-3 agonists containing a biarylethylimidazole pharmacophore. Extensive SAR studies were carried out with different aryl substitutions. This work led to the identification of a compound 2-{2-[4-(pyridin-2-yl)phenyl]ethyl}-5-(2,2-dimethylbutyl)-1H-imidazole 9 with excellent binding affinity (IC(50)=18 nM, hBRS-3) and functional agonist activity (EC(50)=47 nM, 99% activation). After oral administration, compound 9 had sufficient exposure in diet induced obese mice to demonstrate efficacy in lowering food intake and body weight via BRS-3 activation.
Asunto(s)
Imidazoles/química , Imidazoles/uso terapéutico , Obesidad/tratamiento farmacológico , Receptores de Bombesina/agonistas , Receptores de Bombesina/metabolismo , Animales , Peso Corporal/efectos de los fármacos , Ingestión de Alimentos/efectos de los fármacos , Humanos , Imidazoles/farmacocinética , Ratones , Ratas , Relación Estructura-ActividadRESUMEN
We report SAR studies on a novel non-peptidic bombesin receptor subtype-3 (BRS-3) agonist lead series derived from high-throughput screening hit RY-337. This effort led to the discovery of compound 22e with significantly improved potency at both rodent and human BRS-3.